Sermorelin

Sermorelin is a synthetic 29-amino-acid peptide that reproduces the N-terminal active fragment of human growth hormone-releasing hormone (GHRH). The natural GHRH peptide is 44 amino acids long, but decades of structure-function research established that the first 29 amino acids contain essentially all of the receptor-binding and bioactive information of the parent hormone. Sermorelin, sometimes written GRF(1-29) or GHRH(1-29), captures that minimum bioactive sequence in a defined synthetic molecule that has been used extensively in research on the GHRH receptor, the pituitary somatotroph cell, and the broader growth hormone / IGF-1 axis.

The conceptual reason Sermorelin matters in research is that it offers a clean, well-characterized way to probe endogenous growth hormone release. Where exogenous growth hormone replaces or augments the hormone itself, Sermorelin works one step upstream: it engages the GHRH receptor on pituitary somatotroph cells and asks those cells to release the growth hormone they already store. That upstream positioning preserves the natural pulsatile pattern of growth hormone secretion, leaves feedback loops largely intact, and produces a research signal that looks structurally different from direct hormone administration.

Historically, Sermorelin was developed in the 1970s and 1980s as the structure-activity relationship of GHRH became clear, and it received regulatory approval in the United States in 1997 as a diagnostic and treatment agent for growth hormone deficiency. The clinical product was later withdrawn from the market for commercial reasons, not safety reasons, and Sermorelin has continued since then as a research peptide and as a compounded preparation in some clinical-research contexts. Its long history of investigation makes it one of the better-characterized GHRH analogs in the peptide literature.

This page is a plain-English educational reference for readers who want to understand what Sermorelin actually is, how it was developed, how it engages the GHRH receptor, and where it sits relative to other peptides in the broader growth hormone secretagogue landscape. It is not a medical guide, it does not describe a treatment for any individual, and it makes no claims about effects in people who buy the compound for laboratory use. Sermorelin sold as a research peptide is intended for laboratory and analytical purposes only, and the entire discussion below is framed within that context.

Throughout this page, terms that appear repeatedly in the GHRH literature — somatotroph, GHRH-R, pulsatility, IGF-1, somatostatin, secretagogue — are defined as they come up, and the glossary at the end collects them for easy reference. The FAQ addresses the questions that most often arise about Sermorelin specifically and about GHRH-based research more generally.

Sermorelin is a 29-amino-acid synthetic peptide with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg, terminated as the free C-terminal acid (in the most common research form) or as the C-terminal amide in some preparations. The sequence corresponds exactly to amino acids 1 through 29 of human GHRH-44, the full-length natural hormone. The N-terminal tyrosine is essential for receptor binding; small modifications at that residue dramatically reduce activity. The first ten residues contain most of the receptor-binding contacts, and the remaining residues form an amphipathic alpha-helix that stabilizes the binding conformation.

Endogenous GHRH is produced by neurons in the arcuate nucleus of the hypothalamus and is released into the hypothalamic-pituitary portal blood system, where it travels directly to the anterior pituitary gland and binds the GHRH receptor (GHRH-R) on the surface of somatotroph cells. The GHRH receptor is a class B G-protein-coupled receptor that couples primarily to Gs, activating adenylyl cyclase, raising intracellular cAMP, and producing a downstream signaling cascade that triggers exocytosis of stored growth hormone granules. Sermorelin engages the same receptor and the same downstream signaling cascade as natural GHRH, which is why the literature describes it as a "true" GHRH analog rather than a separate secretagogue.

The natural GHRH peptide is 44 amino acids long, but it is rapidly degraded in plasma — primarily by dipeptidyl peptidase-4 (DPP-4), which cleaves between residues 2 and 3, producing the inactive GHRH(3-44) fragment. The half-life of natural GHRH in circulation is short, on the order of minutes. Sermorelin shares this short half-life and the same DPP-4 vulnerability; the GHRH(1-29) sequence preserves the DPP-4 cleavage site between Ala-2 and Asp-3. Later GHRH analogs (CJC-1295 with DAC, Tesamorelin) were specifically designed to resist DPP-4 cleavage and extend the duration of action, but Sermorelin itself was developed before those design strategies were fully worked out and retains the natural sequence with its natural degradation pattern.

Sermorelin is produced commercially through solid-phase peptide synthesis using Fmoc protecting-group chemistry. The crude peptide is purified by reversed-phase HPLC and characterized by mass spectrometry to confirm identity and purity. As a research peptide, it is typically supplied as a lyophilized powder packaged in glass vials, often in 5 mg or 10 mg amounts. The lyophilized form is stable at deep-freeze temperatures for extended periods, and reconstituted material in sterile bacteriostatic water is typically used within several weeks when stored refrigerated.

It is worth being specific about what Sermorelin is not. It is not growth hormone — growth hormone is a 191-amino-acid pituitary protein, and Sermorelin is a 29-amino-acid hypothalamic hormone analog that acts on a completely different receptor and signals the pituitary to release growth hormone rather than acting in its place. It is not a GHRP / ghrelin receptor agonist like Ipamorelin or GHRP-2; those compounds act on a different receptor (the GHS-R/ghrelin receptor) and engage a parallel signaling system. It is not a long-acting peptide like CJC-1295 with DAC; it retains the short native GHRH half-life. And it is not, in research peptide form, an approved medicine in any current regulatory context.

The history of Sermorelin begins with the identification of growth hormone-releasing hormone itself. The existence of a hypothalamic releasing factor for growth hormone had been hypothesized for decades, but isolation and sequencing of the actual peptide came only in the early 1980s. The breakthrough came from an unusual source: pancreatic tumors that produced ectopic growth hormone-releasing activity. In 1982, two independent groups — one led by Roger Guillemin and one by Wylie Vale — sequenced GHRH from pancreatic tumor tissue, and shortly afterward the same peptide was identified in human hypothalamus. The discovery completed the picture of hypothalamic-pituitary releasing factors that had been built up through the 1960s and 1970s and that won Guillemin and Schally a share of the 1977 Nobel Prize in Physiology or Medicine for related earlier work on TRH and somatostatin.

Once the full 44-amino-acid GHRH sequence was in hand, the structure-activity relationship became a major area of investigation. Synthetic fragments of varying lengths were prepared and tested for receptor-binding affinity and for growth hormone-releasing activity in pituitary cell cultures and in animal models. The work established that the N-terminal 29 residues contain essentially all of the bioactive information of the parent peptide. Further truncations (GHRH(1-27), GHRH(1-24)) retained partial activity but with reduced potency. Modifications at the N-terminus dramatically reduced or abolished activity. This work formed the foundation for all subsequent GHRH analog design.

Sermorelin specifically — the GHRH(1-29) sequence — was advanced through clinical-research investigation during the 1980s and 1990s. The compound was studied as a diagnostic agent for evaluating pituitary somatotroph function in suspected growth hormone deficiency and as a candidate treatment for pediatric growth hormone deficiency. The clinical-research data supported use of Sermorelin as both a diagnostic and a treatment agent for that indication, and the U.S. FDA approved the compound (under the brand name Geref) for treatment of pediatric growth hormone deficiency in 1997. The diagnostic indication was also studied, with subcutaneous Sermorelin used to provoke growth hormone release in stimulation testing.

The clinical product Geref was later withdrawn from the U.S. market for commercial rather than safety reasons. The withdrawal reflected the changing economics of pediatric growth hormone deficiency treatment, where recombinant human growth hormone had become the standard of care and the demand for a hypothalamic releasing factor product was insufficient to sustain the commercial product. The withdrawal did not reflect any newly identified safety concern, and Sermorelin has continued since then as a research peptide and in some clinical-research and compounded-preparation contexts.

In parallel with the Sermorelin clinical-research arc, structure-function work on GHRH continued. Researchers identified the DPP-4 cleavage between Ala-2 and Asp-3 as a major route of metabolic clearance and began designing modified analogs that would resist that cleavage. The substitution of D-Ala for L-Ala at position 2 was one early modification; the addition of a fatty acid for albumin binding (as in CJC-1295) was a later approach; and the modification of multiple residues simultaneously (as in Tesamorelin, a [trans-3-hexenoyl]-GHRH(1-44) analog) was another. These later compounds extend the duration of action well beyond what Sermorelin itself achieves, but they all rest on the foundation that the Sermorelin work established about the bioactive GHRH(1-29) sequence and the GHRH receptor.

In contemporary research, Sermorelin remains a useful reference compound — a "minimal GHRH" that engages the receptor with the natural sequence and short natural half-life. It appears in studies that need a short-acting, naturally-shaped GHRH signal, in comparative studies alongside the longer-acting analogs, and in basic investigations of GHRH-R biology and somatotroph cell function.

The science of Sermorelin sits inside the broader biology of the growth hormone axis, and understanding the compound requires a brief tour of that axis. Growth hormone is produced by somatotroph cells of the anterior pituitary gland and released into the systemic circulation in a pulsatile pattern, with major secretory pulses occurring during slow-wave sleep and smaller pulses occurring at intervals during the day. The pulsatile pattern is generated by the interplay of two hypothalamic signals: GHRH, which stimulates growth hormone release, and somatostatin, which inhibits it. The two signals oscillate in a roughly reciprocal pattern, producing the characteristic pulses.

• Sermorelin is a 29-amino-acid GHRH analog corresponding to the bioactive N-terminal fragment of natural GHRH(1-44).
• It acts on the GHRH receptor (GHRH-R), a class B Gs-coupled GPCR on pituitary somatotroph cells.
• Activation raises cAMP, activates PKA, and triggers pulsatile growth hormone release.
• DPP-4 cleavage between Ala-2 and Asp-3 produces the short native half-life characteristic of the natural GHRH sequence.
• Sermorelin preserves the natural pulsatile pattern of GH release rather than producing sustained elevation.

Structurally, Sermorelin is a linear 29-residue peptide with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg. The molecular mass of the parent peptide is approximately 3358 daltons in the free-acid form. The peptide has no intramolecular disulfide bonds and no covalent modifications beyond the standard amide bond backbone, although the C-terminus is sometimes prepared as an amide (Arg-NH2) rather than the free acid, depending on the synthetic protocol.

In aqueous solution at physiological pH, Sermorelin adopts a partially structured conformation. The N-terminal residues 1-10 form a relatively flexible region that contains the principal receptor-binding contacts. The middle and C-terminal residues 14-29 form an amphipathic alpha-helix — a helical segment with hydrophobic residues clustered on one face and hydrophilic residues on the other. This amphipathic helix is a recurrent structural motif in class B GPCR peptide ligands and is essential for the high-affinity receptor binding observed for GHRH analogs.

The relationship between Sermorelin and natural GHRH(1-44) is structurally straightforward: Sermorelin is the natural sequence truncated after residue 29, with no other modifications. The C-terminal residues 30-44 of GHRH-44 do contribute modestly to receptor binding and to plasma stability, but their removal does not substantially compromise receptor activation, consistent with the structure-activity data. This makes Sermorelin essentially a "minimum bioactive GHRH" — the shortest fragment that retains nearly full receptor agonist activity.

A few structural considerations deserve emphasis. The methionine at position 27 is subject to oxidation under air exposure, and oxidized methionine-containing Sermorelin has reduced activity in some assays. This is one reason lyophilized material is generally stored sealed under inert atmosphere or vacuum, and why reconstituted material has a finite useful working life. The peptide is also susceptible to deamidation at the asparagine residues (Asn-8) and to other slow chemical degradation pathways characteristic of peptides of this size.

Stability characteristics are well-defined. Lyophilized Sermorelin stored sealed at -20 °C or below away from light is generally considered stable for extended periods (years, in the published stability data). Reconstituted material in bacteriostatic water stored at 2-8 °C is typically used within several weeks for laboratory work, with single-use aliquoting recommended to avoid repeated freeze-thaw cycles.

Research-grade Sermorelin is produced through solid-phase peptide synthesis with Fmoc protecting-group chemistry, with particular attention to coupling efficiency at the more difficult positions in the sequence. Purification is by reversed-phase HPLC, with identity confirmed by mass spectrometry and purity reported as a percentage of total peptide content. A complete Certificate of Analysis from a reputable supplier reports the sequence, the measured molecular mass, the HPLC purity, and the residual moisture content of the lyophilized powder.

Sermorelin has been used as a research tool across a focused set of themes connected to the GHRH receptor, somatotroph cell function, the pulsatile pattern of growth hormone release, and the broader growth hormone / IGF-1 axis. None of the areas described below represents a therapeutic use of Sermorelin in individuals, and none should be read as suggesting clinical benefit. They are research directions where the compound has been useful as a defined experimental probe.

• GHRH receptor pharmacology and signaling research
• Somatotroph cell biology and growth hormone exocytosis
• Pulsatile growth hormone secretion studies
• Clinical-research stimulation testing protocols
• Comparative secretagogue research (GHRH vs GHRP class)
• Aging and somatopause research

Sermorelin sits in a family of compounds that all engage the growth hormone axis at the level of the pituitary or hypothalamus, but the family contains several pharmacologically distinct subgroups. The table below highlights the key distinctions.

The most direct comparison is with CJC-1295 (both with and without DAC) and Tesamorelin, the other prominent GHRH analogs. All three compounds share the conceptual mechanism of GHRH-receptor agonism on the somatotroph cell, but they differ substantially in duration of action. Sermorelin has the short native GHRH half-life; CJC-1295 without DAC is similarly short-acting but with the D-Ala-2 modification that confers DPP-4 resistance; CJC-1295 with DAC adds an albumin-binding moiety that extends the half-life to roughly a week; Tesamorelin uses an N-terminal trans-3-hexenoyl modification that confers stability while preserving a closer-to-native release pattern. The choice between these compounds in research reflects the desired duration of GHRH signaling.

A second comparison is with the GHRP / ghrelin-receptor agonists (Ipamorelin, GHRP-2, GHRP-6, Hexarelin). These compounds act on a completely different receptor (GHS-R, the ghrelin receptor) and engage a parallel signaling pathway. The GHRH and GHRP signals interact synergistically at the somatotroph cell, and the GHRP class typically suppresses the somatostatin tone that counterregulates GHRH-driven release. Many research protocols combine a GHRH analog like Sermorelin with a GHRP/GHS-R agonist like Ipamorelin to study the synergistic effect.

Sermorelin is also sometimes compared with direct administration of growth hormone itself. Direct growth hormone administration bypasses the somatotroph cell entirely and produces a sustained elevation that does not resemble the natural pulsatile pattern. Sermorelin works upstream and preserves the pulsatile pattern, but it requires functional somatotroph cells and a responsive GHRH receptor for the cascade to produce growth hormone release. The two approaches answer different research questions.

Finally, Sermorelin should be distinguished from the GHRH receptor antagonists (such as the Schally-laboratory MZ-series and the JMR-series compounds), which engage the same receptor but block rather than activate signaling. These antagonists are research tools in studies of GHRH-receptor-mediated processes outside the pituitary, including in some oncology research models.

The Sermorelin literature gives a particular impression: a well-characterized, naturally-shaped GHRH agonist that has been studied for four decades, that has a clear molecular mechanism rooted in GHRH-receptor pharmacology, that had a clinical-research approval arc that produced and then withdrew an approved medicine for commercial reasons, and that remains a reference compound in basic research on the growth hormone axis. The compound's place in the broader peptide research landscape is well-defined: it is the minimum bioactive GHRH, the canonical short-acting GHRH analog, the reference point against which longer-acting analogs and synergistic combinations are measured.

The conceptual foundation of Sermorelin is well grounded. The bioactive role of the N-terminal 29 residues of GHRH was established by careful structure-activity work in the 1980s. The GHRH receptor has been cloned, characterized, and studied at the molecular level. The signaling cascade from receptor activation to growth hormone exocytosis is well understood. The pulsatile pattern of growth hormone release and its regulation by the GHRH/somatostatin balance is a textbook subject in endocrinology.

The clinical-research arc of Sermorelin was substantive. The compound was studied as a diagnostic agent in pituitary function testing and as a treatment for pediatric growth hormone deficiency. The clinical data supported FDA approval in 1997. The product was later withdrawn from the U.S. market for commercial reasons rather than safety reasons, reflecting the dominance of recombinant human growth hormone in the pediatric growth hormone deficiency space and the limited commercial market for a hypothalamic releasing factor product. Sermorelin remains available as a compounded preparation in some jurisdictions and as a research peptide for laboratory use.

Methodologically, Sermorelin research has used recombinant receptor expression systems, primary pituitary cell cultures, immortalized somatotroph cell lines, animal models with intact pituitary function, and human clinical-research protocols. The pharmacokinetic profile of the compound is well-characterized — short half-life, rapid DPP-4 cleavage, modest tissue distribution. The pharmacodynamic profile in terms of growth hormone release is well-characterized as well, with the magnitude and shape of the response well-documented across the dose range that has been studied.

Open questions in the Sermorelin literature are relatively few, because the compound is mature. The more active research questions involve the longer-acting GHRH analogs (CJC-1295 with DAC, Tesamorelin), the synergistic GHRH + GHRP combinations, and the specific applications in particular research contexts where a GHRH stimulus is useful. Sermorelin remains in this landscape as the reference compound — the "minimum GHRH" against which the others are compared.

For students, researchers, and curious readers approaching Sermorelin for the first time, the most accurate framing is that of a well-characterized GHRH receptor agonist with a long and substantive history, a clear and well-understood mechanism, a discontinued approved-medicine arc, and a continuing role as a reference compound in basic research on the growth hormone axis. The compound is supplied for laboratory and analytical use only as a research peptide, and educational discussion of it needs to stay within that framing.

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal active fragment of human growth hormone-releasing hormone (GHRH). It engages the GHRH receptor on pituitary somatotroph cells, activates a Gs/cAMP/PKA signaling cascade, and triggers pulsatile growth hormone release through the natural physiological pathway. The compound was developed through the structure-activity work that followed the 1982 sequencing of GHRH, received FDA approval in 1997 as a treatment for pediatric growth hormone deficiency under the brand name Geref, and was later withdrawn from the U.S. market for commercial rather than safety reasons.

In research, Sermorelin functions as the "minimum bioactive GHRH" — the reference compound for GHRH-receptor pharmacology, somatotroph cell biology, pulsatile secretion studies, and comparative work alongside longer-acting GHRH analogs and the parallel GHS-R agonist class. The short native half-life dominated by DPP-4 cleavage between Ala-2 and Asp-3 is both a defining feature of the compound and the design problem that later analogs (CJC-1295 with DAC, Tesamorelin) were created to address.

This page treats Sermorelin as an educational subject and a research peptide. It is supplied for laboratory and analytical use only. Nothing in the discussion above constitutes medical advice, describes a treatment for any individual, or makes claims about effects in people who purchase the compound for research. The framing throughout reflects the compound's actual status: a well-characterized GHRH receptor agonist with a substantive research history and a continuing role as a reference compound in basic investigation of the growth hormone axis.